US · NNOX · MEDICAL - DEVICES
Nano-X Imaging Ltd. (NNOX) intrinsic value and stock valuation
$0.23as of 2026-11-21 · Mkt cap 69.6M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Nano-X Imaging Ltd. DCF and intrinsic value
InvestorsCraft values NNOX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NNOX’s statements →
Nano-X Imaging Ltd. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $13M | $11.3M | $9.9M | $8.58M | $1.3M |
| Operating income | -$-60.7M | -$-56.75M | -$-62.59M | -$-109.71M | -$-61.56M |
| Net income | -$-75.02M | -$-53.52M | -$-60.78M | -$-105.24M | -$-61.8M |
| EPSd | -$-1.16M | -$-913K | -$-1.08M | -$-2.01M | -$-1.28M |
| Operating cash flow | -$-40.79M | -$-36.6M | -$-44.78M | -$-43.38M | -$-38.07M |
| Capital expenditure | -$-4.21M | -$-2.77M | -$-3.3M | -$-7.17M | -$-23.16M |
| Free cash flow | -$-45M | -$-39.37M | -$-48.08M | -$-50.56M | -$-61.23M |
| Total assets | $162.2M | $210M | $218.7M | $253.9M | $363.2M |
| Total debt | $7.85M | $7.45M | $8.4M | $4.62M | $5.77M |
| Net debt | -$-41.3M | -$-31.86M | -$-47.98M | -$-33.84M | -$-60.87M |
| Total equity | $139.7M | $189.1M | $195.5M | $216.7M | $292.2M |
| Cash and short-term investments | $59.6M | $73.2M | $82.4M | $77.6M | $88.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $13M | $11.3M | $9.9M | $8.58M | $1.3M |
| Cost of revenue | $25.8M | $21.9M | $16.5M | $15.5M | $2.82M |
| Gross profit | -$-12.79M | -$-10.61M | -$-6.59M | -$-6.88M | -$-1.51M |
| Research and development expenses | $19.2M | $20.2M | $26.1M | $26.5M | $17.1M |
| Selling, general and administrative expenses | $27.1M | $25.8M | $28.4M | $45.6M | $41.7M |
| Other expenses | $1.58M | $210K | $1.55M | $190K | $1.18M |
| Operating expenses | $47.9M | $46.1M | $56M | $72.3M | $60.1M |
| Cost and expenses | $73.7M | $68M | $72.5M | $87.8M | $62.9M |
| Interest income | $1.42M | $2.87M | $1.65M | $790K | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $290K |
| Depreciation and amortization | $11.7M | $11.7M | $11.8M | $11.5M | $2.29M |
| Ebitda | -$-49M | -$-45.01M | -$-47.69M | -$-75.7M | -$-59.27M |
| Operating income | -$-60.7M | -$-56.75M | -$-62.59M | -$-109.71M | -$-61.56M |
| Total other income/expenses, net | -$-16.11M | $2.87M | $1.47M | -$-14.67M | -$-290K |
| Income before tax | -$-76.81M | -$-53.87M | -$-61.12M | -$-108.92M | -$-61.85M |
| Income tax expense | -$-1.79M | -$-360K | -$-340K | -$-3.68M | -$-50K |
| Net income | -$-75.02M | -$-53.52M | -$-60.78M | -$-105.24M | -$-61.8M |
| Weighted average shares outstanding | $64.8M | $58.6M | $56.4M | $52.2M | $48.2M |
| Weighted average diluted shares outstanding | $64.8M | $58.6M | $56.4M | $52.2M | $48.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $59.6M | $73.2M | $82.4M | $77.6M | $88.7M |
| Net receivables | $2.01M | $1.8M | $1.48M | $980K | $1.05M |
| Inventory | $3.07M | $1.49M | $2.36M | $2.41M | $3.13M |
| Total current assets | $66.8M | $78.7M | $88.6M | $82.5M | $94.9M |
| Property, plant and equipment, net | $33.2M | $49.2M | $46.9M | $44.7M | $39.2M |
| Goodwill and intangible assets | $60.2M | $70M | $80.6M | $98.6M | $160.1M |
| Long-term investments | $360K | $340K | $330K | $25.2M | $67.8M |
| Total non-current assets | $95.4M | $131.3M | $130M | $171.5M | $268.3M |
| Total assets | $162.2M | $210M | $218.7M | $253.9M | $363.2M |
| Accounts payable | $2.89M | $2.21M | $3.3M | $3.62M | $3.13M |
| Short-term debt | $4.09M | $3.81M | $4.35M | $740K | $1.03M |
| Deferred revenue | $530K | $140K | $540K | $180K | $250K |
| Total current liabilities | $16.9M | $14M | $15.5M | $25.1M | $52.8M |
| Long-term debt | $3.77M | $3.64M | $4.04M | $3.88M | $4.75M |
| Deferred revenue, non-current | $20K | $0.00 | $0.00 | $400K | $410K |
| Total non-current liabilities | $5.54M | $6.91M | $7.61M | $12.2M | $18.3M |
| Capital lease obligations | $4.71M | $4.38M | $4.91M | $1.14M | $1.83M |
| Total liabilities | $22.4M | $20.9M | $23.1M | $37.3M | $71M |
| Common stock | $200K | $180K | $170K | $160K | $150K |
| Retained earnings | -$-448.77M | -$-373.75M | -$-320.23M | -$-259.46M | -$-146.21M |
| Accumulated other comprehensive income (loss) | -$0.00 | -$0.00 | -$-300K | -$-1.97M | -$-610K |
| Total equity | $139.7M | $189.1M | $195.5M | $216.7M | $292.2M |
| Total investments | $10.8M | $34.2M | $26.3M | $64.4M | $89.9M |
| Total debt | $7.85M | $7.45M | $8.4M | $4.62M | $5.77M |
| Net debt | -$-41.3M | -$-31.86M | -$-47.98M | -$-33.84M | -$-60.87M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-75.02M | -$-53.52M | -$-60.78M | -$-105.24M | -$-61.8M |
| Depreciation and amortization | $11.7M | $11.7M | $11.8M | $11.5M | $2.29M |
| Stock-based compensation | $4.19M | $7.26M | $6.84M | $18.6M | $18.8M |
| Change in working capital | $2.77M | -$-1.13M | -$-7.48M | -$-16.95M | $2.75M |
| Accounts receivable | $110K | -$-320K | -$-510K | $70K | -$-40K |
| Inventory | -$-330K | -$-280K | $0.00 | $0.00 | $860K |
| Accounts payable | $290K | -$-1.32M | -$-150K | $470K | $1.72M |
| Net cash provided by operating activities | -$-40.79M | -$-36.6M | -$-44.78M | -$-43.38M | -$-38.07M |
| Investments in property, plant and equipment | -$-4.21M | -$-2.77M | -$-3.3M | -$-7.17M | -$-23.16M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $1.01M | -$-2.86M |
| Net cash used for investing activities | $29.4M | -$-20.05M | $35.4M | $14.6M | -$-116.32M |
| Common stock issued | $21.4M | $37.8M | $27.1M | $950K | $3.58M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $21.4M | $39.5M | $27.3M | $800K | $7.38M |
| Net change in cash | $9.85M | -$-17.07M | $17.9M | -$-28.24M | -$-147.01M |
| Cash at end of period | $49.2M | $39.3M | $56.4M | $38.5M | $66.8M |
| Operating cash flow | -$-40.79M | -$-36.6M | -$-44.78M | -$-43.38M | -$-38.07M |
| Capital expenditure | -$-4.21M | -$-2.77M | -$-3.3M | -$-7.17M | -$-23.16M |
| Free cash flow | -$-45M | -$-39.37M | -$-48.08M | -$-50.56M | -$-61.23M |
Line items
Line items
Line items
About Nano-X Imaging Ltd.
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based software platform envisioned to facilitate medical screening as a service. Nano-X also operates Nanox.MARKETPLACE, a platform designed to connect imaging facilities and customers with radiologists for efficient remote interpretation of medical scans. Additionally, the company provides AI-driven software solutions to a wide range of healthcare entities, including hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers. These solutions are designed to analyze data from existing computed tomography (CT) scans to identify or predict undiagnosed or underdiagnosed medical conditions, such as osteoporosis and cardiovascular disease. Nano-X further offers Teleradiology Services, delivering remote imaging interpretation to radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities, and multi-specialty physician groups. Founded in 2011, Nano-X Imaging Ltd. is headquartered in Neve Ilan, Israel.
- CEO
- Erez I. Meltzer
- Employees
- 197
- Beta
- 1.23
Explore
Frequently asked questions
What is the intrinsic value of Nano-X Imaging Ltd. (NNOX)?
InvestorsCraft does not currently publish an intrinsic value for NNOX. How the IC value is calculated.
Is NNOX undervalued?
InvestorsCraft does not publish an undervaluation signal for NNOX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.